OncoMatch/Clinical Trials/NCT05333328

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Is NCT05333328 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Ovarian function suppression with endocrine treatments for breast cancer.

Phase 4RecruitingGangnam Severance HospitalNCT05333328Data as of May 2026

Treatment: Ovarian function suppression with endocrine treatments — Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: ESR1 overexpression (ER+)

ER+

Required: HER2 (ERBB2) wild-type (HER2-)

HER2-

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify